Visiongain has published a new report on “North America Molecular Diagnostics Market, 2021-2031”. Forecasts By Technology {Polymerase Chain Reaction (Multiplex PCR, Other PCR), Isothermal Nucleic Acid Amplification Technology,In Situ Hybridization, Mass Spectrometry,Chips and Microarrays, Transcription Mediated Amplification, Sequencing, Others}, Application {Oncology (Prostate Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Liver Cancer, Kidney Cancer, Lung Cancer, Blood Cancer, Other Cancer), Pharmacogenomics, Infectious Diseases (Clostridium Difficile,Methicillin-resistant Staphylococcus Aureus, Carbapenem-resistant Bacteria, Vancomycin-resistant Enterococci, Flu, Candida, Respiratory Syncytial Virus, Meningitis,Tuberculosis and Drug-Resistant TBA, Chlamydia, Gastrointestinal Panel Testing, HIV, Gonorrhoea, Hepatitis B, Hepatitis C, Other Infectious Diseases), Genetic Testing (Predictive and Pre-symptomatic Testing, New-born Screening, Other Genetic Testing), Neurological Disease, Cardiovascular Diseases, Microbiology, Others}, Product (Instruments, Reagents), Test Location (Point-of-Care, Over the Counter, Central Laboratories), by Country (U.S., Canada), PLUS COVID-19 Recovery Scenarios.

Visiongain’s lead analyst says: ‘The North Americanmarket for molecular diagnostics was valued at US$4,135.8 million in 2020 and is expected to reachUS$12,058.3 million by 2031. And in 2020, the global demand for molecular diagnosticreagents were priced at US$3,438.4 million and is expected to hit US$10,235.9 million by 2031’.

Download Exclusive Sample of Report @https://www.visiongain.com/report/north-american-mdx-market-2021/#download_sampe_div

How does COVID-19 Outbreak to Offer Lucrative Growth Opportunities?
Essential Role of Diagnostics in Control of Communicable Diseases
Growing Public and Clinical Needs to Drive Molecular Diagnostics Market Growth
Deployment of SARS-CoV-2 Diagnostics Anticipated to Curb the Epidemic Across Geographies

Key Questions Answered by this Report:

• What is the current size of the North America Molecular Diagnostics market? How much will this market be worth from 2021 to 2031?
• What are the main drivers and restraints that will shape the North America Molecular Diagnostics market over the next ten years?
• What are the main segments within the North America Molecular Diagnostics market? How much will each of these segments be worth for the period 2021 to 2031? How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• What are the largest national markets for the North America Molecular Diagnostics? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2031?
• How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
• Which are the leading companies and what are their activities, results, developments, and prospects?
• What are the main trends that will affect the North America Molecular Diagnostics market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities, and threats for the market?
• How will the North America Molecular Diagnostics market evolve over the forecasted period, 2021 to 2031?
• How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?

Molecular Diagnostics to Improve Healthcare Outcomes
To improve health outcomes, molecular diagnostic testing for genetic or pathogenic diseases is necessary to provide easy, fast and reliable testing, particularly in the developed world. For clinical diagnosis of different pathologies, rapid identification of nucleic acids is important. To avoid undertreatment, it is important to recognise persons who need medication for particular pathologies. The quantity of overtreatment that occurs in resistant micro-organisms can also be minimised. This is anticipated to fuel North American molecular diagnostics market over the forecast period from 2021 to 2031.

Get Detailed TOC @ https://www.visiongain.com/report/north-american-mdx-market-2021/#download_sampe_div

Get Insight into the Competitive Landscape, read this report today.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the North American molecular diagnostics market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the molecular diagnostics market.For example, on 1stSeptember 2020, Biocartis Group NV announced the extension of its partnership with LifeArc, an international medical research charity headquartered in the United Kingdom, with a new arrangement aimed at developing highly advanced prototype assays for infectious and immune-related diseases on the fully automated IdyllaTM molecular diagnostics platform of Biocartis.

Companies Profiled

Roche Diagnostics
Abbott
Becton, Dickinson, and Company
bioMérieux SA
Bio-Rad Laboratories, Inc.
Dako (Agilent Technologies)
Danaher
FOUNDATION MEDICINE, INC.
Genomic Health (Exact Sciences Corporation)
Hologic, Inc.
Illumina, Inc.
HTG Molecular Diagnostics, Inc.
Grifols, S.A.
QIAGEN
Siemens Healthcare GmbH
Sysmex Corporation
Need industry data? Please contact us today.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

About Visiongain
Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.
-
SOURCE Visiongain Limited.